Oaktop Capital Management II, L.P. Q3 vs. Q4 2022: Analyzing the Biggest Fund Holdings Changes

Oaktop Capital Management II, L.P. is a well-known investment management firm with a diverse portfolio in technology, healthcare, finance, and other industries. The firm just recently filed its 13F form with the Securities and Exchange Commission (SEC), outlining its holdings for the Q3 2022 and Q4 2022 reporting periods. In this blog post, we will analyze the firm's most significant holdings changes during this period and provide insights on the nature of these changes.

KLA Corporation (KLAC)

Oaktop's highest holding company is KLA Corporation, holding steady with 395,750 shares from Q3 to Q4 of 2022. However, the value of these shares has increased by 24.6%, from $119,766 to $149,209. KLA Corporation is a leading supplier of process control and yield management solutions for semiconductor manufacturing and related industries and has been a vital part of Oaktop's portfolio for years.

LAM Research Corporation (LRCX)

Oaktop's holding in LAM Research Corporation decreased slightly from 300,246 in Q3 to 269,146 in Q4 2022. However, the overall value of these shares only decreased by 2.9%, from $109,890 to $113,122. LRCX is a manufacturer of semiconductor capital equipment, focusing on the production of advanced lithography and etch tools used in the fabrication of various microchips.

Analog Devices Inc. (ADI)

Oaktop remained faithful to the Analog Devices Inc. (ADI) in Q3 and Q4, holding 466,196 shares each reporting period. However, the value of these shares increased by 17.7%, from $64,959 to $76,470. Analog Devices designs and manufactures analog, mixed-signal, and digital signal processing integrated circuits used in various commercial and industrial applications.

Bristol Myers Squibb Co. (BMY)

Oaktop's position in Bristol Myers Squibb Co. (BMY) stayed constant in both Q3 and Q4 of 2022, each with 679,991 shares. However, the value of these holdings only increased slightly by 1.2%, from $48,340 to $48,925. BMS researches, develops, and manufactures pharmaceutical products used to treat cancer, cardiovascular, and immunologic diseases, among others.

Aspen Aerogels Inc. (ASPN)

Oaktop's position in Aspen Aerogels Inc. (ASPN) remained unchanged in both Q3 and Q4, holding 3,194,758 shares. However, the value of the shares increased by 27.9%, from $29,455 to $37,666. Aspen Aerogels designs, develops, and manufactures energy-saving insulation products, bringing energy efficiency, sustainability, and safety to various industrial sectors.

Conclusion

Oaktop Capital Management II, L.P. Q3 to Q4 2022 filings indicate the fund's continuing focus on high-tech companies. Despite some sales and purchases of stocks, Oaktop remained true to its investment strategy of holding technology stocks for long periods. The changes highlit in this post give insights on the way Oaktop's portfolio evolves during these two quarters and underline the very selective approach of the investment management firm.